Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.

Diane M Donegan,Rosario Pivonello,Antonio Stigliano,Pina Lardo,Tara Kearney,Emese Mezosi,Ezio Ghigo,Roberta Giordano,Cary N Mariash,Richard A Feelders,Kirsteen Donaldson,Borje Darpo,Hongqi Xue,Joseph M Custodio,Austin L Hand,Andreas G Moraitis

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists（2023）

引用 0|浏览7

暂无评分

摘要

At all doses studied, relacorilant consistently demonstrated a lack of QTc prolongation in healthy volunteers and patients with CS, including in the TQT study. Ongoing phase 3 studies will help further establish the overall benefit-risk profile of relacorilant.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要